Home / Journals International Journal of Clinical Oncology and Cancer Research / Immune Response in Cancer, What Immunotherapies Can Do for Us?
Immune Response in Cancer, What Immunotherapies Can Do for Us?
Submission DeadlineAug. 30, 2020

Submission Guidelines: http://www.sciencepublishinggroup.org/home/submission

Lead Guest Editor
Marconi R Barros
Faculty of Pharmacy, Centro Universitário Brasileiro, Recife, Brazil
Guest Editors
  • Aldo Venuti
    Tumor Immunology and Immunotherapy, Istituto Regina Elena, Istituti Fisioterapici Ospitalieri, Roma, Italy
  • Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, USA
  • Sjoerd H Van der Burg
    Department of Clinical Oncology, Leiden University Medical Centre, Leiden, Netherlands
  • Zihai Li
    Hollings Cancer Center, Medical University of South Carolina, Charleston, USA
  • Alexis M Kalergis
    Departamento de Genética Molecular y Microbiologia, Pontifical Catholic University of Chile, Santiago, Chile
  • Mingjun Wang
    Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, USA
Cancer is mysterious pathology. Although so many studies and considerable advances in cancer pathogenesis comprehension, diagnosis and treatment, it is still difficult to understand how it occurs and how can be prevented and eliminated. The various spots it can emerge and the complex interaction with other cells in cancer medium contribute to that. However, from a decade to now, new immunotherapeutic procedures have gained more attention, mainly because their promising results. New immune cells have been discovered and other, which has not had much importance, has now their values being recognized gradually. Therefore, this special issue aims to introduce and discuss new immunotherapies methodologies which are demonstrating great potential for solid cancers treatment. Basic and clinical studies will be demonstrated, and new possibilities for drug development can be suggested and tested.
Biomarkers for cancer occurrence and for clinical establishment and prognosis are also on focus, showing the importance for the application of therapeutic approaches during the initial stages of cancer progression. Also, preventive measures will be encouraged, such as the development of new vaccines approaches or the improvement of existing ones. Cancer pathogenesis, paying special attention to the immunologic aspects, will be discussed and new pathways will be revealed. New interactions between cytokines and receptors as well as new roles may be suggested, and the same may occurs for immune and non-immune cells. Gradually, the interactions between these two types of cells have being revealed and demonstrated new immunotherapeutic possibilities due to the gain on understanding of cancer pathogenesis. Knowledge about recent immune cell subtypes functions may be deepened, as well as their interaction with other immune cells. At last, the evaluation of TLR multiple roles, chemokines targets, non-immune obscured functions and the double roles of immune cells may be also object of studies and reviews, and new hypothesis may be drawn.
Aims and Scope:
  1. Cancer Immunology
  2. Cancer Immunotherapy
  3. Immune Response
  4. Drug Development
  5. Biomarkers
  6. Clinical Studies
Guidelines for Submission
Manuscripts should be formatted according to the guidelines for authors
(see: http://www.sciencepublishinggroup.org/journal/guideforauthors?journalid=273).

Please download the template to format your manuscript.

Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186